Literature DB >> 16493331

[Antinuclear antibodies].

Claire Goulvestre1.   

Abstract

Antinuclear antibodies react with various nuclear autoantigens. Testing for them is critical for diagnosing connective tissue diseases, but they may be also found in other inflammatory diseases and in the elderly. They constitute a group of heterogeneous autoantibodies, and their specificity helps to discriminate between various connective tissue diseases. Screening for total antinuclear antibodies is generally performed by indirect immunofluorescence on HEp2 cells. In the presence of antinuclear antibodies, anti-dsDNA antibodies and anti-ENA (extractable nuclear antigens) antibodies must be sought. Positivity for IgG anti-dsDNA antibodies is highly characteristic of systemic lupus. A rapid increase in their titer suggests visceral, particularly renal, involvement. Anti-Sm antibodies are also characteristic of systemic lupus, while anti-JO1 and anti-Scl70 antibodies suggest, respectively, myositis and diffuse systemic sclerosis. Antibody titers do not provide information about disease course. The presence of anti-Ro/SSA antibodies during pregnancy requires a workup for cardiac conduction disturbances in the fetus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493331     DOI: 10.1016/s0755-4982(06)74572-9

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  2 in total

1.  Serum antinuclear antibodies associate with worse prognosis in AQP4-positive neuromyelitis optica spectrum disorder.

Authors:  Rong Fan; Yuefeng Zhang; Yunqi Xu; Jiayi Tong; Zhigang Chen; Meifeng Gu; Wenkui Fan; Yong Chen; Fuhua Peng; Ying Jiang
Journal:  Brain Behav       Date:  2020-12-14       Impact factor: 2.708

2.  High frequency of Smith autoantibodies in Omani patients with systemic lupus erythematosus.

Authors:  Ali A Al-Jabri; Amal K Al-Gahdani; Ibtisam Al-Shuaili
Journal:  Rheumatol Int       Date:  2009-11       Impact factor: 3.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.